Recent research reveals that **typhoid antibiotic resistance** accounts for 87% of India's economic burden related to this common infectious disease. According to a study in The Lancet Regional Health Southeast Asia, the total economic toll reached Rs 123 billion in 2023. Specifically, fluoroquinolone-resistant infections drive the majority of these costs. This financial strain disproportionately affects young children and their families. Consequently, researchers advocate for the urgent introduction of the typhoid conjugate vaccine into the national immunisation schedule.

Economic Drivers of Typhoid Antibiotic Resistance

Fluoroquinolone-resistant infections are the primary catalyst for the rising medical expenses in India. Moreover, these resistant strains accounted for at least 87 per cent of the disease-related economic burden last year. Although fluoroquinolones typically treat severe infections effectively, rising resistance levels complicate recovery. Therefore, patients often face longer hospital stays and require more expensive alternative treatments. Furthermore, the study indicates that households bear 91 per cent of these medical expenses directly. Notably, nearly 70,000 families across the country faced catastrophic health expenditures due to the illness.

Vulnerable Populations and High-Burden States

Children under the age of 10 incur the highest economic burden, contributing to over half of the national costs. Additionally, the study identified specific geographic hotspots for the disease. Five states—Maharashtra, Uttar Pradesh, Andhra Pradesh (including Telangana), Tamil Nadu, and West Bengal—account for 51 per cent of the national financial impact. Typhoid spreads through contaminated food or water and causes high fever, fatigue, and stomach pain. However, targeted health financing policies could alleviate the financial pressure on these high-burden regions. Specifically, enhancing antibiotic resistance control remains a critical priority for national health authorities.

Frequently Asked Questions

Q1: How much does typhoid fever cost India annually?

A study estimated that typhoid fever imposed an economic burden of Rs 123 billion in 2023. Households bore 91 per cent of these costs, often resulting in severe financial strain.

Q2: Why is fluoroquinolone resistance a major concern?

Fluoroquinolone resistance drives 87 per cent of the total economic burden. Because first-line antibiotics become less effective, treatment becomes more complex and expensive for families.

Q3: Which age group is most affected by typhoid in India?

Children under the age of 10 contribute to more than half of the total economic costs. This vulnerability highlights the need for effective pediatric vaccination strategies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Antibiotic resistance fuels 87% of India's typhoid economic burden: Study - ETHealthworld


2. Mogasale, V. V., et al. (2026). Burden of typhoid fever and antimicrobial resistance in India (2023): a modelling study. The Lancet Regional Health Southeast Asia.


3. Coalition Against Typhoid. (2025). Potential of typhoid conjugate vaccines in India.